Olga Anne has completed her PhD at the age of 37 years from Moscow Chemical Technological University, Russian. She is the senior researcher/professor of Klaipeda University, Lithuania. She has over 60 publications in pre-reviewed journals and 17of them are in ISI WOS journals that have been cited over 45 times.
Ecological Engineering, Biosystems Engineering, Bioengineering
My research activity and scientific production primarily deal with the pathobiology of several respiratory disorders such as asthma, COPD, interstitial pulmonary diseases and lung cancer, and also regard the molecular mechanisms underlying the therapeutic actions of the main drugs used for their treatments. In particular, my current studies are focusing on the role of “mitogen-activated protein kinases” in the signal transduction pathways activated by cytokines, growth factors and oxidative stress in primary cultures of human pulmonary endothelial cells, bronchial epithelial cells, lung cancer cell lines, and pulmonary fibroblasts. A major research interest concerns the activation and inhibition of these enzymes in cell death and proliferation, as well as in development and pharmacological modulation of lung inflammation and remodelling. I am also particularly interested in the recent advances referring to the biological therapies of asthma, with special regard to anti-IgE treatment, with whom I am familiar since ten years ago. I have been actively involved in many basic studies and clinical trials, among which the most relevant include: (i) “Role of signal transduction pathways activated by oxidative stress or proliferative stimuli in the development and progression of lung cancer: possible diagnostic, prognostic, therapeutic and preventive implications”, financed by a grant of the Italian Ministry for University and Scientific Research (n. 2003061034 – years 2003-2004); (ii) International study “CIGE025A2425”, financed by Novartis and aimed to evaluate the clinical effects in severe, uncontrolled allergic asthma, of the humanized anti-IgE monoclonal antibody omalizumab (years 2005-2006); (iii) A Pan-European open randomised study comparing the efficacy and cost-effectiveness of Symbicort Maintenance and Reliever Therapy – Symbicort SMART – using a maintenance dose of Symbicort 160/4.5 ?g, 1 or 2 inhalations twice daily in the treatment of persistent asthma – EUROSMART (D5890L00022 – years 2007-2008). I conducted clinical research according to GCP. My scientific production comprehensively includes over 100 book chapters, reviews and original articles published in both national and international, peer-reviewed journals.
pathobiology of several respiratory disorders such as asthma, COPD, interstitial pulmonary diseases and lung cancer, and also regard the molecular mechanisms underlying the therapeutic actions of the main drugs used for their treatments
Yuri E Dubrova was born in Kiev and spent his school years there. He obtained a BSc degree in Biology at Kiev State University and a PhD in Genetics at N.I. Vavilov Institute of General Genetics in Moscow. He then undertook a number of research projects in population genetics there. In 1994 he moved to the Department of Genetics University of Leicester to study the genetic effects of exposure to ionising radiation and chemical mutagens in mammals. Working there, he has developed a number of sensitive approaches for monitoring mutation induction in the mammalian germline. Analysing mutation rates at minisatellite loci in four cohorts of irradiated families from Belarus, Ukraine, Kazakhstan and Russia he obtained the first experimental evidence for radiation-induction of human germline mutation. Using another class of tandem repeat DNA loci, he analysed the pattern of mutation induction in the germline of male mice exposed to a variety of mutagens, including ionising radiation, alkylating agents and anticancer drugs. He has recently analysed the genome-wide effects of exposure to ionising radiation on mutation induction in the mouse germline.
Analysis of Germline Mutation Induction in Humans and Mice Following Exposure to Ionising Radiation, Chemical Mutagens and Some Anticancer Drugs
Dr. Karen G.Mulkijanyan currently holds positions of Head of the Department of Preclinical Pharmacological Research at Tbilisi State Medical University (TSMU) I.Kutateladze Institute of Pharmacochemistry and full Professor at the Caucasus International University Faculty of Medicine. He obtained MS in Biochemistry in 1981, and PhD in Pharmacy in 2005. Dr. Mulkijanyan was a manager/ key investigator of research projects funded by CRDF Global/GRDF, STCU, GNSF/SRSNF. As Organizing Committee Member, he arranged several international congresses and conferences on pharmacology and pharmacy. Dr. K.Mulkijanyan co-authored more than 100 scientific publications, 30 presentations at international scientific meetings and 2 patents in pharmacology. Dr. K.Mulkijanyan is Founder and President of the Georgian Association for Laboratory Animal Science, a member of the Association of Professional Chemists of Georgia and Association of University Technology Managers.
Pharmacology of anti-inflammatory, ulcer preventive, burn and wound healing drugs; analysis of structure-activity relationship (SAR) and prediction of bioactivity of natural, modified and synthesized compounds; intellectual property protection; technology transfer and technology commercialization, use and care of laboratory animals.
Omid Sabzevari (OS) is a scientist in the field of Mechanistic Toxicology and Pharmacology, Xenobiotics Analysis and Food Safety. OS was listed among Top 1% Scientists of the World according to ESI/ISI in May 2012. OS is a Temporary Adviser of WHO and a scientific member of the Expert Panel on Food Safety, JECFA. OS is President of Iranian Association of Pharmaceutical Scientists (IranAPS) and President of Iranian Society of Toxicology (IranTox). He is also the Head of Basic and Clinical Toxicology Research Centre, TUMS.